Agios Pharmaceuticals, Inc. (AGIO) Stock Forecast
AGIO analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 4.40 / 5 from 10 analysts
- Price target
- $46.00 average of analyst targets
- Upside to target
- +46.9% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-1.32
- 52-week range
- $22.34 – $45.49
AGIO analyst ratings
10 analystsNumber of analysts at each rating.
AGIO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
AGIO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.22 | −$1.58 | −$1.06 | −$1.78 | +31.3% | 8 |
| Current fiscal year (2026) | −$5.72 | −$6.49 | −$5.28 | −$7.12 | +19.7% | 8 |
| Next fiscal year (2027) | −$3.74 | −$4.90 | −$2.12 | −$5.75 | +34.9% | 10 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
AGIO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $51.9M | $47.0M | $55.4M | +303.0% | 10 |
| Current fiscal year (2026) | $178.0M | $166.0M | $186.4M | +229.5% | 10 |
| Next fiscal year (2027) | $347.1M | $222.1M | $428.1M | +95.0% | 10 |
AGIO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
AGIO revenue: reported and forecast
AGIO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.48 | −$1.19 | −$1.19 | −$1.22 | −$1.22 | −17.3% | 0 up · 3 down |
| Current fiscal year (2026) | −$6.20 | −$5.63 | −$5.63 | −$5.71 | −$5.72 | −7.8% | 0 up · 3 down |
| Next fiscal year (2027) | −$4.67 | −$3.86 | −$3.69 | −$3.74 | −$3.74 | −19.9% | 0 up · 3 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
AGIO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; AGIO beat in 7 of 12.
What analysts expect from AGIO
10 analysts cover Agios Pharmaceuticals; their consensus rating is buy (4.40 on a 1–5 scale, where 5 is a strong buy). The average price target is $46.00, 46.9% above the latest close of $31.32. Analysts expect earnings of −$5.72 per share for 2026, +19.7% from a year earlier. For 2027 the average estimate is −$3.74 per share on revenue of $347.1 million. Agios Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: AGIO income statement, AGIO key metrics, AGIO chart. See the AGIO stock overview for the latest quote and news.
AGIO forecast FAQ
What is Agios Pharmaceuticals's price target?
The average analyst price target for Agios Pharmaceuticals is $46.00, 46.9% above the latest close of $31.32.
Is Agios Pharmaceuticals a buy, hold or sell?
Of 10 analysts covering Agios Pharmaceuticals, 7 rate it a strong buy, 0 a buy, 3 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Agios Pharmaceuticals's EPS forecast?
Analysts forecast −$5.72 per share for 2026 (range −$6.49 to −$5.28); for 2027 the estimate is −$3.74.
What is Agios Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $178.0 million, growth of 229.5%; for 2027 it is $347.1 million.
When does Agios Pharmaceuticals report earnings?
Agios Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 before the market opens; the EPS estimate is $-1.32.
Does Agios Pharmaceuticals usually beat earnings estimates?
Agios Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.